5Oguz S, Sargin A, Kelekci S, et al. The role of hormone replacement therapy in endometrial polyp formation[J]. Maturitas, 2005,50 : 231-236.
6McGurqan P, Tayor L J, Dully S R, et al. An immunohistochemical comparison of endometrialpolyps from postmenopausal women exposed and not exposed to HRT[J]. Maturitas,2006,53 (4) :454-461.
7McGurqan P, Tayor L J, Duffy S R, et al. Does tamoxifen therapy aff-ect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immtmohistochemical comparison of endornetrial polyps from postmenopausal women exposed and not exposed to tamoxifen[ J]. Maturitas,2006,54(3 ) :252-259.
8Narvekar N, Cameron S, Critchley H O, et al. Low-dose mifepristone inhibits endometrial pro-Liferation and up-regulates androgen recept-or[J]. J Clin Endo-crinol Metab, 2004,89 ( 5 ) : 2491-2497.
9Steinauer J, Pritts E A, Jackson R, et al. SystematiC review of mifepristone for the treatment of uterine leiomyomata[J]. Obstet Gynecol,2004,103 ( 6 ) : 1331-1336.
10Grunberg S M, Weiss M H, Russell C A, et al. Long-term administration of mifepristone ( RU486 ) : Clinical tolerance during extended treatment of meningioma [ J ]. Cancer Invest, 2006, 24 (8) :727-733.
